MedTherapy Biotechnology has officially signed a Memorandum of Understanding (MoU) with Sharda University, marking a strategic collaboration aimed at advanced research, innovation, and talent development in the field of Cancer Gene Therapy.

MedTherapy Biotechnology, founded by leading cancer experts from Harvard University, including alumni of Harvard Medical School and Harvard Business School, along with former Novartis executives, is on a mission to revolutionize Cancer Gene Therapy, making it affordable and accessible for every patient.

With our global headquarters in Boston, USA and state-of-art manufacturing facilities in Delhi-NCR, India, we are developing next-generation Gene Therapy solutions that reduce manufacturing costs by over 70%, making life-saving therapies reachable for the masses.

This MoU with Sharda University will strengthen academic-industry linkages, open doors for joint research, internship programs, and training opportunities, and pave the way for clinical and technological breakthroughs in biotech and healthcare. We look forward to nurturing young minds, sharing scientific excellence, and pushing the boundaries of what’s possible in Gene Therapy, together.